Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Test Type (Serology, Stool Antigen, and Urea Breath), Test Method (Laboratory Based and Point-of-Care), and End User (Hospitals, Clinics, and Diagnostic Laboratories)
- Report Code : BMIRE00027539
- Pages : 117
The helicobacter pylori (H. pylori) non-invasive testing market in North America is expected to grow from US$ 211.77 million in 2022 to US$ 265.21 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2022 to 2028.
Increasing Prevalence of H. pylori Bacterial Infection Bolsters North America Helicobacter Pylori (H. pylori)
Non-invasive Testing Market
The H. pylori infection is usually developed during infancy but remains asymptomatic, with long-standing clinical symptoms, including gastritis, peptic ulcer disease, and stomach cancer. According to World Health Organization (WHO), in developed countries, the prevalence rate of H. pylori is low, i.e., 50%. Further, the prevalence of gastric disease is significantly higher in the geriatric population as aging increases the risk of H. pylori infection. Over time, aging leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining that contributes to the growing prevalence of infection among older people. According to WHO, the population of people aged 60 years and above is expected to rise. With the subsequent increase in the geriatric population, the demand for primary care services, including screening, assessment, and management of clinical and functional comorbidities, is also growing. These statistics determine the rising need for diagnostics across North America, which is expected to boost the growth of the Helicobacter pylori (H. pylori) non-invasive testing market in the region during the forecast period.
Market Overview
The North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into the US, Canada, and Mexico. North America is the largest market for Helicobacter pylori (H. pylori) non-invasive testing across the globe. The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the Helicobacter pylori (H. pylori) non-invasive testing market in North America. The US Department of Health and Human Services report states that ~30-40% of the population in the US suffer from H. pylori infection. Moreover, H. pylori infection is more common in the Hispanic and Black populations in the country due to socioeconomic factors, including low income, less education, household crowding, and immigration into the US. According to the ClinMed International Library report, the first-line drug regimens for the treatment of H. pylori by the Food and Drug Administration (FDA) include proton pump inhibitors (PPI) and two antibiotics or bismuth subsalicylate, acid suppressors, and two antibiotics. With approved first-line drug regimens, there exists resistance to utility. For example, the US eradication rates using these regimens accounted for 75% owing to H. pylori resistance to standard antibiotics. “Clarithromycin” and “Metronidazole” has the highest rate of resistance, and factors associated with resistance involve ethnicity, age, geographic region, and active versus inactive ulcer disease. Hence, The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the Helicobacter pylori (H. pylori) non-invasive testing market in the region.
North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Revenue and Forecast to 2028 (US$ Million)
North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Segmentation
The North America helicobacter pylori (H. pylori) non-invasive testing market is segmented on test type, test method, end user, and country.
Based on test type, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market. Based on test method, the North America Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022. Based on end user, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022. Based on country, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into the US, Canada, and Mexico. Further, the US dominated the market in 2022. Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc. are the leading companies operating in the helicobacter pylori (H. pylori) non-invasive testing market in North America.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – By Test Type
1.3.2 North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market – By Test Method
1.3.3 North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market – By End User
1.3.4 North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Helicobacter Pylori (H. pylori ) Non-Invasive Testing Market – Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Increasing prevalence of H. pylori bacterial infection
5.1.2 New Product Launches & FDA Approvals for Noninvasive Tests
5.1.3 Spreading Awareness Among Individuals Regarding Diagnosis of H. pylori
5.1.4 Rise in Investments by Pharmaceutical Companies
5.2 Key Market Restraints
5.2.1 Low Diagnosis Rate
5.3 Key Market Opportunities
5.3.1 Increasing Number of Conferences and Events for Research
5.3.2 Introduction of Artificial Intelligence
5.4 Future Trends
5.4.1 Increasing Use of Home-Based POC Devices
5.4.2 Diagnosis for Resistance
5.5 Impact Analysis
6. Helicobacter pylori (H. pylori ) Non-Invasive Testing Market– North America Analysis
6.1 North America Helicobacter pylori (H. pylori) Non-Invasive Testing Market Revenue Forecast and Analysis
7. North America Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis– by Test Type
7.1 Overview
7.2 North America Helicobacter pylori (H. pylori ) Non-invasive Testing Market, By Test Type 2022 & 2028 (%)
7.3 Serology Test
7.3.1 Overview
7.3.2 North America Serology Test Market Revenue and Forecasts to 2028 (US$ Mn)
7.4 Stool Antigen Test
7.4.1 Overview
7.4.2 North America Stool Antigen Test Market Revenue and Forecasts to 2028 (US$ Mn)
7.5 Urea Breath Test
7.5.1 Overview
7.5.2 North America Urea Breath Test Market Revenue and Forecasts to 2028 (US$ Mn)
8. North America Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis– by Test Method
8.1 Overview
8.2 North America Helicobacter pylori (H. pylori) Non-invasive Testing Market, By Test Method 2022 & 2028 (%)
8.3 Laboratory Based Tests
8.3.1 Overview
8.3.2 North America Laboratory Based Tests Market Revenue and Forecasts to 2028 (US$ Mn)
8.4 Point Of Care Tests
8.4.1 Overview
8.4.2 North America Point of Care Tests Market Revenue and Forecasts to 2028 (US$ Mn)
9. North America Helicobacter pylori (H. pylori ) Non-invasive Testing Market Analysis– by End User
9.1 Overview
9.2 North America Helicobacter pylori (H. pylori ) Non-invasive Testing Market, By End User 2018 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 North America Hospitals Market Revenue and Forecasts to 2028 (US$ Mn)
9.4 Clinics
9.4.1 Overview
9.4.2 North America Clinics Market Revenue and Forecasts to 2028 (US$ Mn)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 North America Diagnostic Laboratories Market Revenue and Forecasts to 2028 (US$ Mn)
10. North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market Revenue and Forecasts to 2028 – Country Analysis
10.1 Overview
10.1.1 North America: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Country, 2022 & 2028 (%)
10.1.1.1 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type, 2020–2028 (US$ Million)
10.1.1.1.4 US: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method, 2020–2028 (US$ Million)
10.1.1.1.5 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User, 2020–2028 (US$ Million)
10.1.1.2 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type, 2020–2028 (US$ Million)
10.1.1.2.4 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method, 2020–2028 (US$ Million)
10.1.1.2.5 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User, 2020–2028 (US$ Million)
10.1.1.3 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type, 2020–2028 (US$ Million)
10.1.1.3.4 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method, 2020–2028 (US$ Million)
10.1.1.3.5 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User, 2020–2028 (US$ Million)
11. Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profile
12.1 DiaSorin S.p.A.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Meridian Bioscience, Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 QuidelOrtho Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Abbott Laboratories
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 CerTest Biotec
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sekisui Diagnostics
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Coris BioConcept
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Bio-Rad Laboratories, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. US Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. US Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 3. US Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4. Canada: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 5. Canada Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 7. Mexico: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method– Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 10. Recent Inorganic Growth Strategies in the Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market
Table 11. Recent Organic Growth Strategies in the Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market Segmentation
Figure 2. North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, By Country
Figure 3. North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Overview
Figure 4. Urea Breath Segment Held Largest Share of Test Type Segment in North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market
Figure 5. Mexico is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. North America Helicobacter pylori Non-Invasive Testing Market Impact Analysis of Driver and Restraints
Figure 9. North America Helicobacter pylori (H. pylori) Non-Invasive Testing Market– Revenue Forecast and Analysis – 2020 – 2028
Figure 10. North America Helicobacter pylori (H. pylori) Noninvasive Testing Market, by Test Type 2022 & 2028 (%)
Figure 11. North America Serology Test Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. North America Stool Antigen Test Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. North America Urea Breath Test Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. North America Helicobacter pylori (H. pylori) Noninvasive Testing Market, by Test Method 2022 & 2028 (%)
Figure 15. North America Laboratory Based Tests Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. North America Point Of Care Tests Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. North America Helicobacter pylori (H. pylori) Noninvasive Testing Market, by End User 2018 & 2028 (%)
Figure 18. North America Hospitals Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. North America Clinics Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 20. North America Diagnostic Laboratories Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. North America: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Key Country – Revenue (2022) (US$ Million)
Figure 22. North America: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Country, 2022 & 2028 (%)
Figure 23. US: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Canada: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Mexico: Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Growth Strategies in the Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America helicobacter pylori (H. pylori) non-invasive testing market
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the North America helicobacter pylori (H. pylori) non-invasive testing market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the helicobacter pylori (H. pylori) non-invasive testing market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
The List of Companies – North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market
● Abbott Laboratories
● Bio-Rad Laboratories Inc.
● CerTest Biotec; Coris BioConcept
● Coris BioConcept
● DiaSorin S.p.A.
● Meridian Bioscience Inc.
● QuidelOrtho Corporation
● Sekisui Diagnostics
● Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd
● Thermo Fisher Scientific Inc.
At 3.8% CAGR, the North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market is speculated to be worth US$ 265.21 Million by 2028, says The Insight Partners
According to The Insight Partners’ research, the North America helicobacter pylori (H. pylori) non-invasive testing market was valued at US$ 211.77 million in 2022 and is expected to reach US$ 265.21 million by 2028, registering an annual growth rate of 3.8% from 2022 to 2028. Increasing prevalence of H. pylori bacterial infection and new product launches & FDA approvals for noninvasive tests are the critical factors attributed to the market expansion.
Diagnosis of H. pylori infection is performed by invasive (endoscopy and endoscopic biopsy for histopathology, culture, and rapid urease test) and non-invasive (urea breath tests, stool antigen test, and serological tests) methods. The diagnostic decisions are based on the prevalence of H. pylori infection and age-related gastric cancer incidence. For instance, non-invasive techniques are preferred mostly where gastric cancer incidence is low.
However, increased accuracy is obtained by using multiple diagnostic tests. Although these tests have high accuracy, the endoscopy-based diagnostic methods are not recommended for screening purposes, mainly due to their invasiveness, high cost, and unavailability
Furthermore, the American College of Gastroenterology (ACG) and Canadian Association of Gastroenterology, considering the adverse effects that may occur because of endoscopy, suggest the use of upper gastrointestinal endoscopy in patients who have dyspeptic symptoms and are above 60 years or if the patient belongs to a high-risk family or a region with gastric cancer. However, in a few European countries, endoscopy is recommended for patients over the age of 45 years who have a high chance of developing gastric cancer. Thus, the growing awareness spread by governments for proper diagnosis has led to the advent of breakthrough techniques, expected to fuel the market’s growth. Further, in 2020, RedHill Biopharma launched a nationwide H. pylori disease state educational field led by its sales force. The launch is intended to provide greater awareness to healthcare professionals regarding the risk of H. pylori infection and the growing resistance of H. pylori to standard care of antibiotics, leading to 25-40% failure of current therapies.
On the contrary, very low diagnosis rate hurdles the growth of North America helicobacter pylori (H. pylori) non-invasive testing market.
Based on test type, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market in 2022 with a share of 46.8%, amassing US$ 99.04 million. It is projected to garner US$ 130.11 million by 2028 to expand at 4.7% CAGR during 2022–2028. Based on test method, the North America Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022 with a share of 75.6%, amassing US$ 160.20 million. It is projected to garner US$ 202.47 million by 2028 to expand at 4.0% CAGR during 2022–2028. Based on end user, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022 with a share of 59.5%, amassing US$ 125.90 million. It is projected to garner US$ 160.21 million by 2028 to expand at 4.1% CAGR during 2022–2028. Our regional analysis states that US captured 70.8% market share in 2022. It was assessed at US$ 150.20 million in 2022 and is likely to hit US$ 186.02 million by 2028, exhibiting a CAGR of 3.6% during the forecast period.
Key players dominating the North America helicobacter pylori (H. pylori) non-invasive testing market are Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc.
Below are mentioned a few key market developments by major players:
In Dec 2021, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. In April 2020, Meridian Bioscience, Inc. has completed the acquisition of Exalenz Bioscience Ltd., the Modiin, Israel-based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.
Related Reports
- $3,000.00 – $5,000.00
